Focus on incretin-based therapies: targeting the core defects of type 2 diabetes (Q37835612)

24 August 2017

1 reference

title

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes (English)

1 reference

24 August 2017

0 references

1

Paul S Jellinger

1 reference

PubMed ID

21293084

24 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

24 August 2017

Postgraduate Medicine

1 reference

24 August 2017

123

1 reference

24 August 2017

1

1 reference

24 August 2017

53-65

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

24 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

beta-cell failure in diabetes and preservation by clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Metabolic consequences of hyperglycemia and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

The structure and function of CD26 in the T-cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Beta-cell mass plasticity in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Unraveling the science of incretin biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2245

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.01.2245

1 reference

24 August 2017

1 reference

PubMed ID

21293084